Review



anti human mouse keap1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Proteintech anti human mouse keap1
    ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of <t>Keap1</t> and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).
    Anti Human Mouse Keap1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1339 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+mouse+keap1/KEAP1+Antibody/pmc12047442-20-0-5
    Average 96 stars, based on 1339 article reviews
    anti human mouse keap1 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Targeting HMGB2 acts as dual immunomodulator by bolstering CD8 + T cell function and inhibiting tumor growth in hepatocellular carcinoma"

    Article Title: Targeting HMGB2 acts as dual immunomodulator by bolstering CD8 + T cell function and inhibiting tumor growth in hepatocellular carcinoma

    Journal: Science Advances

    doi: 10.1126/sciadv.ads8597

    ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of Keap1 and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).
    Figure Legend Snippet: ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of Keap1 and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).

    Techniques Used: Expressing, Knock-Out, Ubiquitin Proteomics, Western Blot, Recombinant, Immunofluorescence, Staining, Labeling

    Markers and article numbers of antibodies. PE, phycoerythrin; FITC, fluorescein isothiocyanate; APC, antigen-presenting cell; HRP, horseradish peroxidase; mAb, monoclonal antibody.
    Figure Legend Snippet: Markers and article numbers of antibodies. PE, phycoerythrin; FITC, fluorescein isothiocyanate; APC, antigen-presenting cell; HRP, horseradish peroxidase; mAb, monoclonal antibody.

    Techniques Used: Ubiquitin Proteomics, Purification, In Vivo

    Names and sequence of primers. F, forward; R, reverse.
    Figure Legend Snippet: Names and sequence of primers. F, forward; R, reverse.

    Techniques Used: Sequencing

    Related Articles

    Expressing:


    Knock-Out:


    Ubiquitin Proteomics:


    Western Blot:


    Recombinant:


    Immunofluorescence:


    Staining:


    Labeling:


    Purification:


    In Vivo:


    Sequencing:




    Similar Products

    93
    R&D Systems mouse anti keap1
    Mouse Anti Keap1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+mouse+keap1/Human%2FMouse%2FRat+Keap1+Antibody/pmc12350482-106-27-29
    Average 93 stars, based on 1 article reviews
    mouse anti keap1 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    96
    Proteintech anti human mouse keap1
    ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of <t>Keap1</t> and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).
    Anti Human Mouse Keap1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+mouse+keap1/KEAP1+Antibody/pmc12047442-20-0-5
    Average 96 stars, based on 1 article reviews
    anti human mouse keap1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Proteintech anti human mouse nrf2 antibody
    ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of <t>Keap1</t> and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).
    Anti Human Mouse Nrf2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+mouse+keap1/KEAP1+Antibody/pm40257700-128-24-27
    Average 96 stars, based on 1 article reviews
    anti human mouse nrf2 antibody - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    93
    R&D Systems Hematology mab3024
    ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of <t>Keap1</t> and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).
    Mab3024, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+mouse+keap1/Human%2FMouse%2FRat+Keap1+Antibody/pm38151169-80-48-49
    Average 93 stars, based on 1 article reviews
    mab3024 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems protein keap1
    ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of <t>Keap1</t> and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).
    Protein Keap1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+mouse+keap1/Human%2FMouse%2FRat+Keap1+Antibody/pm38151169-80-44-49
    Average 93 stars, based on 1 article reviews
    protein keap1 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems Hematology mouse anti keap1
    ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of <t>Keap1</t> and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).
    Mouse Anti Keap1, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+mouse+keap1/Human%2FMouse%2FRat+Keap1+Antibody/pm38191622-113-34-38
    Average 93 stars, based on 1 article reviews
    mouse anti keap1 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of Keap1 and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).

    Journal: Science Advances

    Article Title: Targeting HMGB2 acts as dual immunomodulator by bolstering CD8 + T cell function and inhibiting tumor growth in hepatocellular carcinoma

    doi: 10.1126/sciadv.ads8597

    Figure Lengend Snippet: ( A ) Location of differential accessible ATAC-seq peaks in NC and Hmgb2 -cKO CD8 + T cells. 3′UTR, 3′ untranslated region; 5′UTR, 5′ untranslated region. ( B ) Chromatin accessibility changes of genes associated with effector function and mitochondrial transcription factors. ( C ) The correlation between Hmgb2 , Tfam , and Tfb1m expression in CD8 + T cells from murine scRNA-seq data. ( D ) mRNA levels of Keap1 and Nfe2l2 in NC and Hmgb2 -cKO CD8 + T cells ( n = 6). ( E ) mRNA levels of ARE genes in NC and Hmgb2 -cKO CD8 + T cells ( n = 3). ( F ) Protein changes of KEAP1 and NRF2 after Hmgb2 knockout. ( G ) The ubiquitination of NRF2 after Hmgb2 knockout. IB, immunoblot. ( H ) Protein changes of KEAP1 and NRF2 after stimulation of mouse recombinant HMGB2 protein and IN-1. NC CD8 + T cells were treated with recombinant HMGB2 protein (500 ng/ml) and/or IN-1 (10 μM) for 48 hours. ( I ) The ubiquitination of NRF2 after cell treatment as in (H). ( J ) Immunofluorescence staining of spontaneous HCC tissues in NC and Hmgb2 -cKO mice. NRF2 + KEAP1 − CD8 + T cells were labeled. Scale bars, 20 μm (left) and 10 μm (right). HP, high power field. ( K ) Seahorse extracellular flux analysis of OCR in different CD8 + T cell groups ( n = 6 to 8) after cell treatment as in (H). ( L ) Quantification of seahorse extracellular flux analysis of OCR of different CD8 + T cells as in (K). Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Pearson test for (C) Student’s t test for (D), (E), and (J). Two-way ANOVA test for (L).

    Article Snippet: Anti-human/mouse KEAP1 , 10503-2-AP , Proteintech, China.

    Techniques: Expressing, Knock-Out, Ubiquitin Proteomics, Western Blot, Recombinant, Immunofluorescence, Staining, Labeling

    Markers and article numbers of antibodies. PE, phycoerythrin; FITC, fluorescein isothiocyanate; APC, antigen-presenting cell; HRP, horseradish peroxidase; mAb, monoclonal antibody.

    Journal: Science Advances

    Article Title: Targeting HMGB2 acts as dual immunomodulator by bolstering CD8 + T cell function and inhibiting tumor growth in hepatocellular carcinoma

    doi: 10.1126/sciadv.ads8597

    Figure Lengend Snippet: Markers and article numbers of antibodies. PE, phycoerythrin; FITC, fluorescein isothiocyanate; APC, antigen-presenting cell; HRP, horseradish peroxidase; mAb, monoclonal antibody.

    Article Snippet: Anti-human/mouse KEAP1 , 10503-2-AP , Proteintech, China.

    Techniques: Ubiquitin Proteomics, Purification, In Vivo

    Names and sequence of primers. F, forward; R, reverse.

    Journal: Science Advances

    Article Title: Targeting HMGB2 acts as dual immunomodulator by bolstering CD8 + T cell function and inhibiting tumor growth in hepatocellular carcinoma

    doi: 10.1126/sciadv.ads8597

    Figure Lengend Snippet: Names and sequence of primers. F, forward; R, reverse.

    Article Snippet: Anti-human/mouse KEAP1 , 10503-2-AP , Proteintech, China.

    Techniques: Sequencing